Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden
Arthritis & Rheumatology · 2026-01 · 78 (1) · 223-230
DOI: 10.1002/art.43327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 21.09.2025. Verfasst von Meghan Anderson und 15 weiteren Autor:innen. Beteiligte Einrichtung: University of Pennsylvania, Philadelphia, and New York University (NYU) School of Medicine, New York, New York. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMHD NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Objective
Vacuoles, E1‐ubiquitin–activating enzyme, X‐linked, autoinflammatory, somatic (VEXAS) syndrome is a progressive systemic autoinflammatory disorder caused by somatic variants in UBA1 in blood. Previous analyses have shown discordant disease penetrance. In this study, we examine the associations between demographic features and UBA1 variant allele frequency (VAF) with disease manifestations.
Methods
Whole exome sequencing data from 192,584 participants from Geisinger MyCode Community Health Initiative and Mount Sinai Bio Me Biobank were analyzed for disease‐causing variants in UBA1 . Clinical manifestations were analyzed across individuals with the UBA1 variant.
Results
Nine UBA1 variants (VAF range 2.9%–79%) in 23 participants (69.6% men) were identified. Cases with high VAF (>20%) developed macrocytic anemia more often (87.5%) than patients with low VAF (≤20%) variants (27%; P = 0.009). Specifically, at the time of genetic testing, 87.5% of high VAF cases had macrocytic anemia compared with 13.3% of low VAF cases ( P = 0.001). However, there was no significant difference in the development of anemia or thrombocytopenia ( P = 0.53). In two high VAF cases, macrocytosis developed more than five years before the time of sample collection, followed by anemia approximately at the time of sample collection. In one low VAF case with other inflammatory symptoms, macrocytic anemia did not develop until five years after sample collection.
Conclusion
VEXAS syndrome disease severity and penetrance increase at higher VAFs. Low VAF cases demonstrate incomplete penetrance, and the disease tends to be milder in those with it. Female individuals are enriched in lower VAFs and have milder symptoms, suggesting a protective role against disease severity. Low VAF cases, especially ≤10%, can be initially asymptomatic and later develop disease. image
Autor:innen und Institutionen
- University of Pennsylvania, Philadelphia, and New York University (NYU) School of Medicine, New York, New York.
- NYU School of Medicine, New York, New York.
- Icahn School of Medicine at Mount Sinai, New York, New York.
- National Cancer Institute, NIH, Rockville, Maryland.
- Geisinger, Danville, Pennsylvania.
ORCID-Profile: Meghan Anderson, Ashley Richardson, Eitan Carroll, David B Beck
Förderung
- NIMHD NIH HHS
- NCATS NIH HHS
Zitieren
APA
Anderson, M., Ercelen, D., Richardson, A., Kim, J., Torene, R. I., Sirenko, M., Haley, J. S., Cook, A., Hill, W., Dove, J., Retterer, K., Carroll, E., Carey, D. J., Asgari, S., Stewart, D. R., & Beck, D. B. (2026). Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden. Arthritis & Rheumatology, 78(1), 223-230. https://doi.org/10.1002/art.43327
Vancouver
Anderson M, Ercelen D, Richardson A, Kim J, Torene RI, Sirenko M, et al. Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden. Arthritis & Rheumatology. 2026;78(1):223-230. doi:10.1002/art.43327
BibTeX
@article{Anderson2026,
author = {Anderson, Meghan and Ercelen, Defne and Richardson, Ashley and Kim, Jung and Torene, Rebecca I and Sirenko, Maria and Haley, Jeremy S and Cook, Adam and Hill, Wesley and Dove, James and Retterer, Kyle and Carroll, Eitan and Carey, David J and Asgari, Samira and Stewart, Douglas R and Beck, David B},
title = {Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden},
journal = {Arthritis & Rheumatology},
year = {2026},
volume = {78},
number = {1},
pages = {223--230},
doi = {10.1002/art.43327}
}
EUVIMED